Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033; Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

(INR In Lacs, Except EPS) Quarter Ended Nine Montl Year Ended Ended SI No. Particulars 31-12-20 31-12-19 30-09-20 31-12-19 31-12-20 31-03-20 (Unaudited) (Unaudited) (Unaudited (Unaudited (Unaudited) (Audited) Revenue from operations 29.917.44 45 584 80 26.285 90 116.462.13 112.455.06 136.321.96 Other Income 504.95 77.44 348.15 256.55 103.08 559.67 117,021.80 112,803.21 136,578.51 Ш Total Income (I+II) 30,020.52 46,089.75 26,363.34 IV Expenses 78.147.91 63.978.71 (a) Cost of materials consumed 20,668 47 33.190.22 15.032.37 79.083.88 (b) Purchase of Stock-in-Trade 1,691.92 1,852.59 4,078.01 1,317.63 5,018.33 4,600.90 (c) Changes in inventories of finished goods, work-in-progress 1,251.11 (935.59) 3,102.16 6,039.27 13,815.73 17,249.15 and stock-in-trade (d) Employee benefits expense 5.893.54 1.758.24 2.032.03 1.701.22 5,742.07 7.474.23 1.875.24 2,388.98 (e) Finance costs 186.05 140.49 615.68 551.14 (f) Depreciation and amortization expense 618.59 619.46 607.68 1,848.11 1,794.51 2,407.20 ,836.51 9,150 82 8,855.36 12,328.06 (g) Other expenses .040.37 3,670.70 Total expenses 29,214.75 40,569.90 25,213.25 106,497.65 100,291.10 125,532.40 Profit before tax and exceptional items (III-IV) 805.77 5,519.85 1,150.09 10,524.15 12,512.11 11,046.11 Exceptional items (Refer note 6) 1,000.00 805.77 9,524.15 VII Profit before tax (V-VI) 5,519.85 1,150.09 12,512.11 11,046.11 VIII Tax Expense (1) Current Tax 186.74 2,468,42 2.538.94 1.466.18 (2) Deferred Tax 19.25 (86.38)(40.28)(92.22)(17.58) (96.89)1,379.80 289,06 3,176.36 Total Tax Expense 205.99 2.376.20 2,442.05 Profit for the period (VII-VIII) IX 599.78 4,140.05 861.03 7,147.95 9,335.75 8,604.06 Other comprehensive income Items that will not be reclassified to profit or loss (i) Changes in fair value of FVTOCI equity instruments 14:70 60.25 36.56 109.06 6.40 (143.03) (42.50) (42.50) (10.30)(127.50)(30.90)(170.23) (ii) Remeasurement of net defined benefit plans (iii) Income tax relating to these items 11.43 0.8 (4.91)19.15 9.31 92.80 Other comprehensive income for the period (net of tax) (16.37)18,56 21.35 0.71 (15.19)(220.46)Total comprehensive income for the period (IX+X) 583.41 4,158,61 882.38 7.148.66 9,320.56 8.383.60 id up equity share capital (Face value Rs 10/- each) 2,066.78 2,066.78 2,066.78 2,066.78 2,066.78 2,066.78 Earnings per share (of Rs. 10 each) (not annualised): 20.03 (a) Basic 2.90 4.17 34.58 45.17 41.63

Notes:

(b) Diluted

1 The Unaudited Standalone Financial results for the quarter and nine months ended December 30, 2020 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on February 05, 2021. The Statutory Auditors have carried out a limited review of financial results for the quarter and nine months ended December 31, 2020 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Limited Review report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com

20.03

417

34 58

45 17

41 63

2.90

- 2 The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the financial results. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company, has used internal and external sources of information. Based on the Company assessment, no material impact has been noted. Considering that it is a dynamic and evolving situation, the management will continue to closely monitor and evaluate the impact of any material change in macro-economic and other related factors, which may have bearing on the Company's operations.
- 3 The interim Standalone financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- 4 The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical and Formulation.
- 5 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Indian Parliament approval and Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 6 Exceptional item represents a one-time expense on account of fraud committed by two employees of the Company in collusion with 16 dealers and distributors and distributors had sold the goods in cash at reduced price to different customers. However, the invoices were raised in the name of Company's authorised debtors. The Company has filled FIR on July 04, 2020 in P.S. Janjgir District, Janjgir-Champa, Chhattisgarh. The total amount involved in the fraud is approximately INR 2,000 lakhs. After internal investigation in the matter, the Company estimates that approximately INR 1,000 lakhs will be recovered. Therefore, Company had recognized the provision of INR 1,000 lakhs during the quarter ended June 30, 2020. The Company is of the view that there is no significant impact of aforesaid fraud on the general business conditions, financial position, profit & loss and liquidity position, except for the amounts already recognized.
- 7 Previous period figures have been re-grouped and/ or re-arranged wherever necessary to make their classification comparable with the current period

Place Delhi Date February 05, 2021 COMPANY SECRETARY Rajesh Aggarwal Managing Director DIN: 00576872

on behalf of the Board

DEVESH PAREKH & CO.

S S KOTHARI MEHTA & COMPANY

Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi - 110020

Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura, Delhi-110034

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of the Insecticides (India) Limited for the quarter and nine months ended December 31, 2020 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Insecticides (India) Limited
New Delhi

Review Report on the Standalone Unaudited Financial Results

- We have reviewed the accompanying statement of unaudited standalone financial results of Insecticides
 (India) Limited ("the Company") for the quarter and nine months ended December 31, 2020 ("the
 Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation
 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, as amended (the
 "Listing Regulations").
- 2. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The preparation of the statement is in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards (Ind-AS)- prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and. Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.







S S KOTHARI MEHTA & COMPANY

DEVESH PAREKH & CO.

Chartered Accountants Plot No. 68, Okhla Industrial Area, Phase-III New Delhi -110020 Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura, Delhi-119934

- 5. We draw attention to note no. 6 to the statement highlighting the fraud committed by two employees of the Company in collision with Company's dealers & distributors and FIR filed by the management of the Company against them. Based on the internal assessment & enquiry, Company has made a provision of Rs. 1000 Lacs during the quarter ended June 2020 and shown it as an exceptional item. Further, Company is of the view that there is no significant impact of the committed fraud on the business conditions of the Company, its liquidity position and has concluded that no material adjustments are required in the financial statements.
- 6. We further draw attention to note no. 2 to the statement which describes the uncertainties and the impact of Covid-19 pandemic on the Company's operations and results as assessed by the management.

Our conclusion is not modified in respect of matters stated in para 5 & 6 above.

For S S Kothari Mehta & Company

Chartered Accountants

Firm's registration number: 000756N

Harish Gupta Partner

Membership number: 098336

UDIN: 21098336 AAAAAL 8628

RED ACC

Place: New Delhi Date: February 5, 2021 For Devesh Parekh & Co.

Chartered Accountants

Firm's registration number: 013338N

Devesh Parekh

Partner

Membership number: 092160

UDIN: 21092160 AAAAFS 1221

Place: New Delhi Date: February 5, 2021

Insecticides (India) Limited

CIN: L65991DL1996PLC083909, Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033; Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

(INP In Lacs Event EPS)

Particulars Other Income Other Income Total Income (I+II) Expenses a) Cost of materials consumed (b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense	31-12-20 (Unaudited) 29.917 44 103.08 30,020.52 20,668.47 1,691.92	30-09-20 (Unaudited) 45,584.80 504.95 46,089.75	31-12-19 (Unaudited) 26,285 90 77 44 26,363.34	31-12-20 (Unaudited) 116,462.13 559.67 117,021.80	31-12-19 (Unaudited) 112,455.06 348.15 112,803.21	31-03-20 (Audited) 136,321.96 256.55
Other Income Fotal Income (I+II) Expenses (a) Cost of materials consumed (b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	29,917 44 103.08 30,020.52 20,668.47 1,691.92	45,584.80 504.95 46,089.75	26,285.90 77.44 26,363.34	116,462.13 559.67	112,455.06 348.15	136,321.96 256.55
Other Income Fotal Income (I+II) Expenses (a) Cost of materials consumed (b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	103.08 30,020.52 20,668.47 1,691.92	504 95 46,089.75 33,190 22	77.44 26,363.34	559.67	348.15	256.55
Other Income Fotal Income (I+II) Expenses (a) Cost of materials consumed (b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	103.08 30,020.52 20,668.47 1,691.92	504 95 46,089.75 33,190 22	77.44 26,363.34	559.67	348.15	256.55
Total Income (I+II) Expenses a) Cost of materials consumed (b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	30,020.52 20,668.47 1,691.92	46,089.75 33,190.22	26,363.34			
Expenses (a) Cost of materials consumed (b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20,668.47 1,691.92	33,190.22		117,021.00		136,578.51
(a) Cost of materials consumed (b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,691.92		15 000 00		112,000.21	100,070.01
(b) Purchase of Stock-in-Trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,691.92		15.032.37	78.147.91	63.978.71	79,083.88
stock-in-trade		1,852.59	1,317.63	5,018.33	4,078.01	4,600.90
stock-in-trade		The same of the sa		ALL RESIDENCE		
(d) Employee benefits expense	1,251.11	(935.59)	3,102.16	6,039.27	13,815.73	17,249.15
	1,758.24	2,032.03	1,701.22	5,742.07	5,893.54	7,474.23
(e)Finance costs	186.05	140.49	615.68	551.14	1,875.24	2,388.98
(f) Depreciation and amortization expense	618.59	619.46	607,68	1,848.11	1,794,51	2,407.20
(g) Other expenses	3,040.37	3,670.70	2,836.51	9,150.82	8,855.36	12,328.06
Total expenses	29,214.75	40,569.90	25,213.25	106,497.65	100,291.10	125,532.40
Profit before tax, exceptional items and share of net profit of						
investment accounted for using equity method (III-IV)	805.77	5,519.85	1,150.09	10,524.15	12,512.11	11,046.11
Exceptional items (Refer note 6)	A SECOND			1,000.00	-	
Profit before tax and share of net profit of investment accounted for	905.77	£ 510.05	1.150.00	0.524.65	12 512 11	11.045.11
using equity method (V-VI)	805.77	5,519.85	1,150.09	9,524.15	12,512.11	11,046.11
Share of net profit of joint venture accounted for using the equity	15.07	20 58	29 37	63 94	66.95	87.25
the state of the s						
Profit Before Tax (VII+VIII)	820.84	5,540.43	1,179.46	9,588.09	12,579.06	11,133.36
Tax Expense	Management .			200		
	Section 1					2,538.94
And the state of t						(96.89)
						2,442.05
Profit for the period (IX-X)	614.85	4,160.63	890.40	7,211.89	9,402.70	8,691.31
Other comprehensive income						
Items that will not be reclassified to profit or loss				San Division		
(i) Changes in fair value of FVTOCI equity instruments	14.70	60.25	36.56	109.06	6.40	(143.03)
(ii) Remeasurement of net defined benefit plans	(42.50)	(42.50)	(10.30)	(127.50)	(30.90)	(170.23)
(iii) Share of Other comprehensive income of joint venture accounted	(0.40)	(0.41)	(0.82)	(1 22)	(2.44)	(4.54)
	THE RESERVE AND ADDRESS OF THE PARTY OF THE		-0-1	U.S. A. S.		
						93.95
Other comprehensive income for the period (net of tax)	(16.68)	18.26	20.73	(0.21)	(17.02)	(223.85)
Total comprehensive income for the period (XI+XII)	598.17	4,178.89	911.13	7,211.68	9,385.68	8,467.46
Paid up equity share capital (Face value Rs 10/- each)	2,066.78	2,066.78	2,066.78	2,066.78	2,066.78	2,066.78
Earnings per share (of Rs. 10 each) (not annualised):				A STATE OF		
	2.97	20.13	4 30	34.89	45 49	42.05
		100000000000000000000000000000000000000		1 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		42.05
CI BEEF COCCE	(g) Other expenses Total expenses Profit before tax, exceptional items and share of net profit of investment accounted for using equity method (III-IV) Exceptional items (Refer note 6) Profit before tax and share of net profit of investment accounted for using equity method (V-VI) Share of net profit of joint venture accounted for using the equity method Profit Before Tax (VII+VIII) Tax Expense (1) Current Tax (2) Deferred Tax Total Tax Expense Profit for the period (IX-X) Other comprehensive income Items that will not be reclassified to profit or loss (i) Changes in fair value of FVTOCI equity instruments (ii) Remeasurement of net defined benefit plans (iii) Share of Other comprehensive income of joint venture accounted for using equity method (iv) Income tax relating to these items Other comprehensive income for the period (net of tax) Total comprehensive income for the period (NI+XII)	(g) Other expenses Total expenses Total expenses Profit before tax, exceptional items and share of net profit of investment accounted for using equity method (III-IV) Exceptional items (Refer note 6) Profit before tax and share of net profit of investment accounted for using equity method (V-VI) Share of net profit of joint venture accounted for using the equity method Profit Before Tax (VII+VIII) Tax Expense (1) Current Tax (2) Deferred Tax Total Tax Expense Profit for the period (IX-X) Other comprehensive income Items that will not be reclassified to profit or loss (ii) Changes in fair value of FVTOCI equity instruments (iii) Remeasurement of net defined benefit plans (iii) Share of Other comprehensive income of joint venture accounted for using equity method (iv) Income tax relating to these items Other comprehensive income for the period (net of tax) Total comprehensive income for the period (NI+XII) Sys.17 Total comprehensive income for the period (XI+XII) Paid up equity share capital (Face value Rs 10/- each) Earnings per share (of Rs. 10 each) (not annualised): (a) Basic	Total expenses 3,040.37 3,670.70 Total expenses 29,214.75 40,569.90 Profit before tax, exceptional items and share of net profit of investment accounted for using equity method (III-IV) Exceptional items (Refer note 6) Profit before tax and share of net profit of investment accounted for using equity method (V-VI) Share of net profit of joint venture accounted for using the equity method Profit Before Tax (VII+VIII) Tax Expense (1) Current Tax (2) Deferred Tax 186.74 (1) 295 (86.38) Total Tax Expense Profit for the period (IX-X) Other comprehensive income Items that will not be reclassified to profit or loss (ii) Changes in fair value of FVTOCI equity instruments (ii) Remeasurement of net defined benefit plans (iii) Share of Other comprehensive income of joint venture accounted for using equity method (iv) Income tax relating to these items Other comprehensive income for the period (net of tax) Total comprehensive income for the period (xI+XII) Sys.17 Total comprehensive income for the period (xI+XII) Paid up equity share capital (Face value Rs 10/- each) Earnings per share (of Rs. 10 each) (not annualised): (a) Basic 2.97 20.13	3,040.37 3,670.70 2,836.51	3,040.37 3,670.70 2,836.51 9,150.82 29,214.75 40,569.90 25,213.25 106,497,65 29,214.75 40,569.90 25,213.25 106,497,65 29,214.75 40,569.90 25,213.25 106,497,65 29,214.75 40,569.90 25,213.25 106,497,65 29,214.75 40,569.90 25,213.25 106,497,65 29,214.75 40,569.90 25,213.25 106,497,65 29,213.25 1,150.09 10,524.15 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,000.00 20,	3,040.37 3,670.70 2,836.51 9,150.82 8,855.36 29,214.75 40,569.90 25,213.25 106,497.65 100,291.10 Profit before tax, exceptional items and share of net profit of investment accounted for using equity method (III-IV) Exceptional items (Refer note 6) 1,000.00 1,0524.15 12,512.11 Exceptional items (Refer note 6) 1,000.00 1,000.00 1,000.00 Profit before tax and share of net profit of investment accounted for using equity method (V-VI) Share of net profit of joint venture accounted for using the equity method (V-VI) Share of net profit of joint venture accounted for using the equity method (III-IV) 820.84 5,540.43 1,179.46 9,588.09 12,579.06 Tax Expense 1,000.00 1,000.00 1,000.00 1,000.00 Cave Expense 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 Cave Expense 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 Cave Expense 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00 1,000.00

Notes:

- The Unaudited Consolidated Financial results for the quarter and nine months ended December 31, 2020 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on February 05, 2021. The Statutory Auditors have carried out a limited review of financial results for the quarter and nine months ended December 31, 2020 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Limited Review report and Quarterly Financial Results are available on the Stock Exchange website at www bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com
- The Group has considered the possible effects that may result from the pandemic relating to COVID-19 on the financial results. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Group, has used internal and external sources of information. Based on the Group assessment, no materia impact has been noted. Considering that it is a dynamic and evolving situation, the management will continue to closely monitor and evaluate the impact of any material change in macro-economic and other related factors, which may have bearing on the Group's operations
- 3 The interim consolidated financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Compa (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- The Group is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical and Formulation
- The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Indian Parliament approval and Presidential assen in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- Exceptional item represents a one-time expense on account of fraud committed by two employees of the Group in collusion with 16 dealers and distributors of the Group. The said dealers and distributors had sold the goods in cash at reduced price to different customers. However, the invoices were raised in the name of Group's authorised debtors. The Group has filed FIR on July 04, 2020 in P.S. Jangiar District, Jangiar-Champa, Chhattisgarh. The total amount involved in the fraud is approximately INR 2,000 lakhs. After internal investigation in the matter, the Group estimates that approximately INR 1,000 lakhs will be recovered. Therefore, Group had recognized the provision of INR 1,000 lakhs during the quarter ended June 30, 2020. The Group is of the view that there is no significant impact of aforesaid fraud on the general business conditions, financial position, profit & loss and liquidity positio except for the amounts already recognized.

7 Previous period figures have been re-grouped and/ or re-arranged wherever necessary to make their classification comparable with the current period (1)

Place: Delhi Date: February 05, 2021

Rajesh Managing Directo

COMPANY SECRETARY

DIN: 00576872

DEVESH PAREKH & CO.

<u>S S K</u>OTHARI M<u>EHTA</u> & COMPANY

Chartered Accountants
Plot No. 68, Okhla Industrial Area, Phase-III
New Delhi -110020

Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura. Delhi-110034

Independent Auditor's Review Report on the Unaudited Consolidated Financial Results of the Insecticides (India) Limited for the quarter and nine months ended December 31, 2020 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Insecticides (India) Limited
New Delhi

Review Report on the Consolidated Unaudited Financial Results

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results of Insecticides (India) Limited ("Parent's or the Company") and its share of the net profit/(loss) after tax and total comprehensive income of its jointly controlled entity, for the quarter and nine months ended December 31, 2020 ("the Statement"), attached herewith, being submitted by the Parent's pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
- 2. This statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting" ('Ind-AS 34'), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entity:

Joint Venture
OAT & IIL India Laboratories Private Limited





DEVESH PAREKH & CO.

<u>S S K</u>OTHARI M<u>EHTA</u> & COMPANY

Chartered Accountants Plot No. 68, Okhla Industrial Area, Phase-III New Delhi -110020 Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura, Delhi-110034

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We draw attention to note no. 6 to the statement highlighting the fraud committed by two employees of the Parent in collision with Parent's dealers & distributors and FIR filed by the management of the Parent against them. Based on the internal assessment & enquiry, Parent has made a provision of Rs. 1000 Lacs during the quarter ended June 2020 and shown it as an exceptional item. Further, Parent is of the view that there is no significant impact of the committed fraud on the business conditions of the Parent, its liquidity position and has concluded that no material adjustments are required in the financial statements.
- 7. We draw attention to note no. 2 on the statement which describes the uncertainties and the impact of Covid-19 pandemic on the Parent's operations and results as assessed by the management.

Our conclusion is not modified in respect of matters stated in para 6 & 7 above.

MEHTA

NEW DELHI

DACCON

8. The consolidated unaudited financial results include the Parent's share of net profit after tax of Rs. 15.07 lakhs and Rs. 63.94 lakhs and total comprehensive income of Rs. 14.76 lakhs and Rs. 63.02 lakhs for the quarter and nine months ended December 31, 2020 respectively, as considered in the consolidated unaudited financial results, in respect of joint controlled entity, based on their interim financial results which have not been reviewed by their auditors. According to information and explanations given to us by the Management, these interim results are not material to the Parent.

For S S Kothari Mehta & Company

Chartered Accountants

Firm's registration number: 000756N

Harish Gupta

Partner

Membership number: 098336

UDIN: 21098336 A AAAA M 7462

Place: New Delhi

Date: February 5, 2021

For Devesh Parekh & Co.

Chartered Accountants

Firm's registration number: 013338N

Devesh Parekh

Partner

Membership number: 092160

UDIN: 21092160AAAAFT 2103

Place: New Delhi

Date: February 5, 2021